Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.

ABSTRACT:

Background

Ovarian cancer (OV) is the most lethal gynecological cancer in women. We aim to develop a generalized, individualized immune prognostic signature that can stratify and predict overall survival for ovarian cancer.

Methods

The gene expression profiles of ovarian cancer tumor tissue samples were collected from 17 public cohorts, including 2777 cases totally. Single sample gene set enrichment (ssGSEA) analysis was used for the immune genes from ImmPort database to develop an immune-based prognostic score for OV (IPSOV). The signature was trained and validated in six independent datasets (n = 519, 409, 606, 634, 415, 194).

Findings

The IPSOV significantly stratified patients into low- and high-immune risk groups in the training set and in the 5 validation sets (

SUBMITTER: Shen S 

PROVIDER: S-EPMC6412087 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature